De-Risking Infrastructure, Navigating the 2027 CMS Overhaul, and Accelerating Global Theranostic Scale.

April 20–21, 2027 | Indianapolis

About the event

The Radiopharmaceutical Era has moved from the laboratory to the industrial supply chain. Are you built to scale?

The global targeted radioligand therapy (RLT) market is accelerating at an unprecedented pace, driven by breakthrough clinical efficacy and massive cross-border M&A capital. Yet, the industry is colliding with a brutal physical reality: you cannot scale a commercial blockbuster if you cannot secure the isotopes, manufacture the dose, and deliver a decaying product to the patient on time.

Welcome to The Radiopharmaceutical Commercialization & Supply Chain Summit 2027—the only executive-level B2B forum engineered exclusively for the operational, manufacturing, and market access leaders solving the industry’s multi-billion dollar infrastructure bottleneck.

Unlike generalized academic conferences that focus on early-stage biology, this summit is ruthlessly dedicated to CapEx, physical infrastructure, and commercial monetization. Over two intensive days, C-level biotech executives, tier-1 CDMOs, specialized logistics networks, and commercial investors will converge to break down the immediate operational friction points of 2026 and 2027.

Register for this event

Days
Hours
Minutes
Seconds

Who will be there?

  • Biopharma & Biotech End-User:  Chief Operating Officer (COO), VP of Manufacturing & CMC, VP of External Supply Management, Head of Clinical Operations, and Chief Financial Officer (CFO).
  • Contract Development & Manufacturing Organizations: CEO, Chief Commercial Officer, VP of Business Development, and Head of Radiopharmacy Operations.
  • Specialized Logistics, Aviation & Technology Platforms: Head of Supply Chain Logistics, Director of Fleet Telematics, VP of Digital Integration (Chain of Identity), and Heads of Quality Control / Rapid Release.
  • Private Equity, VCs & Market Access Consultancies : Managing Director of Healthcare Investment Banking, General Partner (Life Sciences), VP of Health Economics & Outcomes Research (HEOR), and Director of Pricing & Market Access.
  • Hospital Networks & Regulatory Gatekeepers : Chief Medical Officer (Hospital Network), Director of Nuclear Medicine, and Regulatory Affairs Strategists (FDA/EMA consultants).

Two Days, Three Commercial Tracks

clinical-trials

Isotope Autonomy & Commercial-Scale Manufacturing

  • Beyond the Thorium Ceiling: Commercial-Scale Actinium-225 via Electron-Accelerator & Novel Reactor Pathways.

  • The Terbium-161 Frontier: Preparing the supply chain and chelator infrastructure for dual Auger/Beta emitting radioligands.

  • The CDMO Capacity Squeeze: Structuring long-term commercial manufacturing agreements before Phase III readouts.

  • Automated Benchtop Synthesis: De-risking the supply chain and resolving the nuclear radiochemist shortage using micro-production robotics.

sourcing.png

The "Melting Ice Cube" – Last-Mile Logistics, QC & Regulatory Overhaul

  • Erasing the Quarantine Bottleneck: Implementing rapid sterility testing (RMM/ATP-bioluminescence) for short-half-life radiopharmaceuticals.

  • Navigating the 2026 Regulatory Overhauls: Preparing for the FDA’s Part 212 NPRM and NRC medical licensing deregulation.

  • Hyper-Localization of the Radiopharmacy: Building modular manufacturing cleanrooms physically attached to point-of-care oncology centers.

  • Erasing the “Last-Mile” Blind Spot: Integrating AI-driven Chain of Identity (COI), fleet telematics, and cold chain tracking to sync patient scheduling with cyclotron yields.

thermal.png

Capital, Dosimetry, & The Economics of Theranostics

  • Project Optimus for Radiopharmaceuticals: Implementing the FDA’s new dosage optimization guidance for oncology RLTs.

  • Capitalizing on the CMS CY2026 OPPS Overhaul: Maximizing separate diagnostic reimbursement and utilizing companion diagnostics as deal currency.

  • The Whitespace Beyond PSMA & SSTR: Target discovery, target congestion, and clinical viability in the next generation of radioligand therapies.

  • The Big Pharma Consolidation Strategy: Teardowns of landmark M&A transactions and how mid-market biotechs can compete for cross-border capital.

An Executive Value Proposition

Networking Moments from PEAK

Attendees took a break to connect over ice cream, creating a relaxed space to network and recharge between sessions.

The Networking Reception brought attendees together to explore research, exchange ideas, and engage directly with presenters.

Attendees were also welcomed to attend these meet-ups during the Reception:

  • Industry leaders Meet Up
  • VIP Meet Up

EmpowHER Reception

The women in radiopharma Reception brought attendees together to celebrate the achievements of women in radiopharma, build new connections, and take part in an empowering evening dedicated to uplifting leaders across the industry.

Closed-Door "Buyer-Only" VIP Breakfast

A private breakfast on Day 1 before the general keynote, strictly barring general service providers and software vendors, with one single non-competing Title/Host Sponsor permitted in the room.

AGENDA AT A GLANCE

# Tentative Agenda, Subject to change

Key Benefits for Sponsors

Connect Directly with Senior Decision-Makers Holding Budget Authority

Engage face-to-face with the CEOs, CSOs, VP CMCs, and supply chain heads from leading radiopharma developers, CDMOs, and isotope suppliers the exact buyers evaluating partners and vendors right now.

Position Your Brand as a Radiopharma Thought Leader

Showcase your expertise through prominent speaking slots on the main agenda place your solutions at the center of the industry’s most pressing conversations, from isotope supply to the cGMP rewrite and M&A consolidation.

Generate Qualified Leads Through Pre-Arranged 1-2-1 Meetings

Bypass the noise with a curated meeting program connecting you with prospects matched to your target profile before you arrive turning three days into a full pipeline of warm opportunities.

Maximize Brand Visibility in a Focused, High-Value Market

Stand out in a dedicated radiopharma-only room no competing noise from adjacent modalities with expo, branding, and content placements that put your company in front of every attendee throughout the event.

super early bird rate

Drug Developer Passes (Pharma/Biotech Operators)

$699

Standard Operator Rate: $1299 per delegate

  • Full access to the main 2-day Scientific Conference Programme spanning all technical tracks.
  • Admission to all plenary sessions, panel discussions, and 40+ expert speaker presentations.
  • Access to 8+ hours of dedicated networking, including structured speed networking and the 1-2-1 digital partnering app.
  • Admission to the Evening Drinks Reception at the close of Day One.
  • Full premium hospitality, including daily networking breakfasts, hot lunches, and all scheduled coffee breaks.

Solution Provider Passes (Vendors/CDMOs/Logistics)

$999

Standard Operator Rate: $1699 per delegate

  • Full access to the main 2-day Scientific Conference Programme spanning all technical tracks.
  • Admission to all plenary sessions, panel discussions, and 40+ expert speaker presentations.
  • Access to 8+ hours of dedicated networking, including structured speed networking and the 1-2-1 digital partnering app.
  • Admission to the Evening Drinks Reception at the close of Day One.
  • Full premium hospitality, including daily networking breakfasts, hot lunches, and all scheduled coffee breaks.

FAQs

How will I receive my registration confirmation?

Upon successful submission of your online registration form, a formal confirmation invoice will be issued to you via email. This invoice serves as your official confirmation of booking.

Can I request a payment receipt?

Yes. Payment receipts are issued upon request. Please note that your initial registration invoice does not serve as a receipt; a formal receipt will be generated only after payment has been successfully processed in accordance with the provided payment instructions

What is the policy for cancellations or delegate substitutions?

All bookings are final and non-refundable. However, registrations are fully transferable. If you are unable to attend, a colleague of equivalent professional standing may take your place at no additional charge. Please submit all substitution requests to kathy.young@tgr-events.com prior to the event to update our attendee records.

How can I access the conference papers and presentations after the event?

Following the conclusion of the event, all registered attendees will receive an email containing exclusive access credentials for our post-event presentation portal. Please note that session video recordings are not provided. Additionally, presentation slides are subject to speaker authorization; therefore, availability is determined by individual speakers and cannot be guaranteed for all sessions.

What networking opportunities are available at the event?

The event features multiple structured networking sessions designed to facilitate professional connections. While we curate these sessions to maximize value, we cannot guarantee the attendance or participation of specific individuals, delegates, or organizations.

What networking opportunities are available at the event?

The event features multiple structured networking sessions designed to facilitate professional connections. While we curate these sessions to maximize value, we cannot guarantee the attendance or participation of specific individuals, delegates, or organizations.

Copyright 2026. All rights are reserved with TGR Events